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Abstract
Background: Alternative splicing is a mechanism for increasing protein diversity by excluding or including exons
during post-transcriptional processing. Alternatively spliced proteins are particularly relevant in oncology since
they may contribute to the etiology of cancer, provide selective drug targets, or serve as a marker set for cancer
diagnosis. While conventional identification of splice variants generally targets individual genes, we present here
a new exon-centric array (GeneChip Human Exon 1.0 ST) that allows genome-wide identification of differential
splice variation, and concurrently provides a flexible and inclusive analysis of gene expression.
Results: We analyzed 20 paired tumor-normal colon cancer samples using a microarray designed to detect over
one million putative exons that can be virtually assembled into potential gene-level transcripts according to
various levels of prior supporting evidence. Analysis of high confidence (empirically supported) transcripts
identified 160 differentially expressed genes, with 42 genes occupying a network impacting cell proliferation and
another twenty nine genes with unknown functions. A more speculative analysis, including transcripts based solely
on computational prediction, produced another 160 differentially expressed genes, three-fourths of which have
no previous annotation. We also present a comparison of gene signal estimations from the Exon 1.0 ST and the
U133 Plus 2.0 arrays.
Novel splicing events were predicted by experimental algorithms that compare the relative contribution of each
exon to the cognate transcript intensity in each tissue. The resulting candidate splice variants were validated with
RT-PCR. We found nine genes that were differentially spliced between colon tumors and normal colon tissues,
several of which have not been previously implicated in cancer. Top scoring candidates from our analysis were
also found to substantially overlap with EST-based bioinformatic predictions of alternative splicing in cancer.
Conclusion: Differential expression of high confidence transcripts correlated extremely well with known cancer
genes and pathways, suggesting that the more speculative transcripts, largely based solely on computational
prediction and mostly with no previous annotation, might be novel targets in colon cancer. Five of the identified
splicing events affect mediators of cytoskeletal organization (ACTN1, VCL, CALD1, CTTN, TPM1), two affect
extracellular matrix proteins (FN1, COL6A3) and another participates in integrin signaling (SLC3A2). Altogether
they form a pattern of colon-cancer specific alterations that may particularly impact cell motility.
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Background
Alternative splicing of mRNA transcripts is one mecha-
nism by which genomic complexity is generated from the
surprisingly low number of genes currently estimated
from the human genome sequence. The fraction of
human genes subject to alternative splicing has risen from
5% in early predictions to at least 75% in a recent
genome-wide exon study (Clark et al., in prep.). There are
examples of hundreds of alternative splicing events from
a single gene, which may affect function by adding or
deleting functional domains, changing affinities, and
altering mRNA stability. Variable transcripts from a single
gene are produced combinatorially through the selection
of cassette exons, mutually exclusive exons, retained
introns, alternative 3' or 5' splice sites, and alternative pro-
moters or polyA sites [1].
Specific alterations in splicing patterns have been found
in association with cancers, many of which may play a
functional role in transformation, motility and metastasis
of tumor tissue. Alternative splicing appears to affect key
aspects of neoplasms by altering hormonal signaling,
apoptosis and mediators of cell-cell and cell-matrix inter-
actions. Modifications in functionality may be generated,
for example, through the deletion of a signaling domain,
increased affinity for messenger ligands, or change in
affinity or activity toward extracellular components. The
latter frequently results in increased cell migration and
invasion (For general reviews, see [2,3]). Although in
most cases the relationship between specific splicing
events and the etiology of cancer is largely unproven,
alternative splicing presents novel targets for diagnostic
and therapeutic measures.
Abnormal splicing of several genes has been observed in
tumors of colorectal origin, including CD44 [4,5], MUC2
[6], SRF [7], NCAM [8], MLH, MSH [9] and members of
the Wnt pathway [10]. Some of these alternately spliced
gene products may have therapeutic utility as markers of
the progression of the disease or as drug targets; however
there are insufficient data supporting their relevance in
larger clinical populations. Individual patient differences,
tissue complexity and lack of tools for comprehensive
analysis of splice variation have made the task challeng-
ing.
We have analyzed both differential gene expression and
alternative splicing in a small collection of colon cancers
employing a microarray (GeneChip Human Exon 1.0 ST)
targeting over a million putative exons. The exons can be
virtually reassembled into over 250,000 transcripts
according to a range of annotation sources. The inclusive-
ness of the array design allowed a flexible gene expression
analysis, initially targeting high confidence transcripts
and then extending to a more speculative set.
Cancer-specific splice variations were detected with exper-
imental algorithms and candidate events were subse-
quently validated with RT-PCR. We found several splice
variants, some of which have been previously associated
with cancer, and several which have not. The majority of
the identified splicing events affect mediators of cytoskel-
etal organization, the extracellular matrix or integrin sign-
aling, and may be involved in cell migration and invasion.
Results
Array Design
The GeneChip Human Exon 1.0 ST array was designed to
be as inclusive as possible at the exon level, deriving from
annotations ranging from empirically determined, highly
curated mRNA sequences to ab-initio computational pre-
dictions [11]. The array contains approximately 5.4 mil-
lion 5-µm features (probes) grouped into 1.4 million
probesets interrogating over one million exon clusters
(exon annotations from various sources that overlap by
genomic location). By comparison, the Affymetrix U133
Plus 2.0 gene expression array contains 1.3 million 11-µm
features comprising 54,000 probesets. A Probe Selection
Region (PSR) represents a region of the genome (assem-
bly HG16, Build 34) predicted to act as an integral, coher-
ent unit of transcriptional behavior. In many cases, each
PSR is an exon; in other cases, due to potentially overlap-
ping exon structures, several PSRs may form contiguous,
non-overlapping subsets of a true biological exon. The
median size of PSRs is 123 bp with a minimum of 25 bp.
Probes were not included for some PSRs because the PSR
might be too small or contain highly repeated or other-
wise problematic sequence. About 90% of the PSRs are
represented by 4 probes (a "probeset"). Such redundancy
allows robust statistical algorithms to be used in estimat-
ing presence of signal, relative expression, and existence of
alternative splicing.
The Exon Array does not include a paired mismatch fea-
ture for each perfect match feature, rather surrogate mis-
match intensities are derived from 1000 pooled
"antigenomic" probes with the same GC content as each
perfect match feature [11]. Antigenomic sequences are not
present in the human, rat or mouse genomes.
The Exon Array also serves as a gene-level expression array.
The median number of probes for each RefSeq gene is 30–
40 distributed along the entire length of the transcript, as
compared to 11 probes mostly at the 3' end in the GC
U133 Plus Array.
The plethora of exon architectures (e.g., cassette exons,
mutually exclusive exons, alternative splice sites, alterna-
tive transcriptional starts and stops), the variations in con-
fidences of transcript annotations, and the necessity of
rapidly incorporating new genomic knowledge has led toBMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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a dynamic design for reconstituting exons into genes. A set
of rules was created for virtually assembling the probesets
(exon-level) into transcript clusters (gene-level) based on
the confidence level of the supporting evidence and the
juxtapositions of the exon borders [11]. In general, exons
were merged into clusters depending on whether and how
many higher confidence clusters or exons they overlap,
whether they have common exact splice sites, and
whether single orphan exons are bounded within another
annotation.
The mapping between probesets and transcript clusters is
defined by meta-probeset lists (in order of decreasing con-
fidence):
A) "Core" (17,800 transcript clusters): RefSeq and full-
length GenBank mRNAs;
B) "Extended" (129K transcript clusters): cDNA tran-
scripts, syntenic rat and mouse mRNA, and Ensembl,
microRNA, Mitomap, Vegagene and VegaPseudogene
annotations;
C) "Full" (262K transcript clusters): ab-initio predictions
from Geneid, Genscan, GENSCAN Suboptimal, Exoni-
phy, RNAgene, SgpGene and TWINSCAN
The combination of merging rules and metaprobe sets
means that some transcript clusters in the Extended and
Full sets may contain regions (probesets) that derive from
annotations of different confidence levels. Of the 1.4 mil-
lion probesets, approximately 290,000 are supported by
full-length mRNAs (i.e., the Core set).
Gene-level signal comparison between the U133 Plus 2.0 
and Exon arrays for normal tissue
Prior to analyzing the colon cancer data, we present a brief
comparison of the gene level signals from the exon array
and Affymetrix's standard gene expression array, the U133
Plus 2. For this, we utilize a subset of data from a panel of
11 normal tissues that was assayed in parallel on both
arrays. The approach was to compare the relative signals
from differentially expressed probesets that target the
same transcript clusters on both arrays.
Significant genes were determined by pair-wise compari-
sons between each set of the 11 tissues with p-values at
0.05, 0.001 and 10-8. Genes were accepted into the analy-
sis if they showed significant changes in at least one tissue
type on both arrays and could be mapped to the same
transcript cluster. At a p-value of 0.05, 7829 probesets
from the U133 Plus 2 array and 5507 transcript clusters
from the Core meta-probeset of the exon array were
accepted and mapped to each other. On average, approx-
imately 1.4 probesets from the U133 Plus 2 array mapped
to each transcript cluster on the exon array. This disparity
in numbers results because the U133 Plus 2 array fre-
quently has multiple independent probesets targeting the
same transcript cluster, whereas the probesets are clus-
tered and summarized into a single gene signal estimate
on the exon array. For the 1654 cases of multiple U133
Plus 2 probesets interrogating the same gene, the mean of
the individual signals was used as the signal estimate.
The distribution of signals for these 5507 transcript clus-
ters from the two array types for the breast tissue samples
are shown in Fig. 1. To reduce the possible confounding
effects of alternative splicing on the signal estimation,
breast tissue was chosen rather than, e.g., brain or testes,
which typically show high levels of splice variation. The
most striking indication from the figure is the apparent
shift of low expression signals from U133 Plus 2 (a logged
signal of less than 5) to a relatively higher expression level
(logged signals between 5 and 7) in the exon array. The
U133 Plus 2 also seems to give marginally higher signal at
high expression levels.
Fig. 2 shows the pairwise signal pattern between transcript
clusters from the two arrays. For convenience, the plot has
been divided into quadrants at a logged signal of 5 (about
double the background signal). The apparent shift of low
expression signals in U133 Plus 2 to higher expression in
the exon array is confirmed by the scatterplot. Quadrant
IV (low signal on U133 Plus 2 and higher signal on the
exon array) contains 1158 transcript clusters while the
converse situation in Quadrant II (low signal in the exon
array and higher signal on U133 Plus 2) contains only 448
transcript clusters. The overall correlation of the signals is
0.60, and the linearity of the data appears to be skewed by
the shift of the signals at the low end. As the p-value for
gene selection becomes more stringent, the correlation
increases (data not shown).
Gene-level expression changes in colon cancer for the 
Core and Full gene sets
The initial analysis of expression changes in colon cancer
targeted Core genes, composed of nearly 17,800 transcript
clusters based on highly confident supporting evidence.
Subsequent to ANOVA analysis, a threshold cutoff was set
to p-values less than 0.0015 and at least a 2-fold geometric
change in gene-level expression between normal and
tumor samples. This yielded 134 significantly up-regu-
lated and 26 down-regulated genes in the tumor samples
(see Additional file 1).
The most heavily represented classes of over-expressed
genes in the tumor samples encompass mitosis, the cell
cycle, apoptosis, cell proliferation, and DNA repair and
recombination (34 altogether). One large group involves
RNA processing (16 genes), including at least 4 participat-BMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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ing in RNA splicing. Components or modulators of the
extracellular matrix are also heavily represented (14
genes), many of which have been implicated in cell inva-
sion and metastasis.
Many of the significantly down-regulated genes represent
normal colon functions that are lost as the tissue becomes
undifferentiated, such as Aquaporin 8, which is normally
present only in colon and pancreas [12]. However, the
decreased expression of two hormones, Somatostatin and
PYY, and HIF3A, a negative regulator of hypoxia-induci-
ble genes, may actively potentiate carcinogenesis [13-15].
Pathway analysis (Fig. 3) indicates that the over-expressed
genes largely populate a dense network involved in cell
proliferation and migration, including VEGF-A, PLAU and
MET (HGF receptor), which have been implicated in con-
trol of cellular invasion and in colon cancer specifically
[16,17]. In this mapping, VEGF-A lies at the center of a
network involved in collagen metabolism. Control of cell
proliferation is centered around casein kinase IIa and β-
catenin, which is a key mediator of Wnt signaling [18].
Other functions represented in the network include anti-
apoptosis, proteolysis, chemotaxis and response to
hypoxia.
The gene-level analysis was repeated with the more specu-
lative Full metaprobe set representing 262,000 transcript
clusters, i.e., putative genes generated from exon clusters
without strong empirical support. ANOVA analysis pro-
duced 290 genes with differential expression between nor-
mal and cancerous tissue. Excluding 130 genes that were
also found in the Core gene analysis leaves 160 genes
found only in the expanded analysis, of which 39 have
some annotation (Additional file 2). Of the 121 remain-
ing completely unannotated putative genes, 38 have sig-
nificant expression (a threshold PLIER signal of 15 in 50%
of the samples) in at least one tissue type.
Frequencies of signal values from the Exon and U133 Plus 2 Arrays Figure 1
Frequencies of signal values from the Exon and U133 Plus 2 Arrays. The distribution of log2 (signal + 16) values of 
transcript clusters are shown for the Exon Array (solid line) and the U133 Plus 2 Array (stippled line) for breast tissues.BMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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Workflow for the detection of splice variants
We introduce here a workflow (Fig. 4) for detecting alter-
native splicing events between normal and cancerous
samples using algorithms that normalize exon signals to
the gene-level signal for each sample, followed by a tissue-
specific ANOVA (in MIDAS) or t-test (in the Splicing
Index [SI])[19,20]. Given the limited number of samples,
the various stages of cancer progression and the aberrant
behavior of several sample pairs, the data were expected to
be noisy. To compensate, the data were filtered by multi-
ple methods at both exon-level and gene-level to reduce
problematic cases. Each combination of filtering and
algorithms produced some viable candidates, but the
most stringent filtering generally showed the best consist-
ency with PCR validation results. The method ultimately
producing the highest proportion of true positives was to
retain only: a) exons with a DABG p-value < 0.05, b) genes
with a signal > 70, c) exons with a log ratio between tis-
sues (i.e., the gene-level normalized fold change) > 0.5, d)
Splicing Index p-values < 0.005 and e) Core exons.
Pairwise comparison of signals from the Exon and U133 Plus 2 Arrays Figure 2
Pairwise comparison of signals from the Exon and U133 Plus 2 Arrays. Each dot represents the log2 (signal + 16) val-
ues for the same transcript cluster from the Exon Array (x-axis) and the U133 Plus 2 Array (y-axis) for breast tissues. Bold 
lines at signal value 5 divide the plot into quadrants I-IV for reference.BMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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This filtering method generated 189 putative splicing
events (Additional file 3), including 7 of the 9 genes even-
tually unambiguously validated by PCR (see below).
Another confirmed splicing event in CTTN barely missed
the threshold with a fold change of 0.47. Most of the pos-
itively validated splicing events were concentrated high in
the p-value list, with COL6A3 and ACTN1 as the top two.
The clearest PCR validations generally resulted from can-
didates (e.g., ACTN1,  CALD1) that consistently ranked
highly regardless of the algorithm or filtering method
used. Conversely, most of the negatively performing genes
in PCR validation resulted from attempts to extend the
limits of our search or to test other filtering approaches. In
each case, the candidates were evaluated and further fil-
tered by visualizing the probeset intensities within the
genomic context (Fig. 5).
RT-PCR validation of differential splicing in colon cancer
In order to empirically assess the presence or absence of
putatively spliced exons, PCR primers were designed on
adjacent constitutively expressed exons, in some cases
spanning several target exons. Some of the validated dif-
ferential splicing events are shown in Fig. 6. One of the
two tumor samples characterized as poorly differentiated
was consistently prototypical of the alternative splicing
patterns of these genes (compare the tumor-normal pair
in Lanes 13 and 14). A common artifact affecting RT-PCR
of alternatively spliced mRNAs appears in some of the gels
(ATP2B4, VCL, FN1) as an unidentified band migrating
just below the largest band. This band represents a heter-
oduplex of the two alternatively spliced forms [21,22].
Altogether, forty-three genes were tested by RT-PCR,
drawn primarily from the filtering method described
above. Nine candidate genes (Table 1) showed clear dif-
ferential alternative splicing in colon cancer relative to
normal colon tissue, with two events occurring in
COL6A3. An additional five genes showed positive results
for discriminatory splicing but with some ambiguity. Of
the other tested genes, 13 exhibited alternative splicing
but were not distinctive between normal and cancerous
tissues, and 16 showed no evidence of alternative splicing
(Additional file 4). In total, approximately one-third of
the 43 tested splicing events gave positive results in the
PCR validation. Each of the validated splicing events
derive from the Core annotation set, and are found in Ref-
A dense network of molecular interactions containing differentially expressed Core genes in colon cancer Figure 3
A dense network of molecular interactions containing differentially expressed Core genes in colon cancer. 
Over- or under-expressed genes, respectively, are indicated by a blue or red disk above-right of the gene-product icon. Green 
or red lines represent stimulatory or inhibitory interactions, respectively. Many transcription factors (e.g., p53) and signaling 
kinases (e.g., ERK1) are excluded due to their multiplicity of connections. The general partitioning of the nodes into canonical 
pathways are shown as bold text.BMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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Seq or GenBank, usually as cassette-type or mutually
exclusive exons.
Table 1 also includes the gene-level fold change for each
of the validated splicing events since strong tissue-specific
differences in gene expression may cause misleading
results in the RT-PCR validations. However, all of the
strongly validated events demonstrated a fold change of
less than 2 (two of the ambiguous events were > 2), and
none of these genes appeared as significantly differentially
expressed in the gene-level analysis.
Validated splicing events
Alpha-actinin 1 (ACTN1) and vinculin (VCL) encode
cytoskeletal elements that interact with actin and proba-
bly participate in the attachment of the cytoskeleton to the
membrane. Exons 19a and 19b of ACTN1 appear to be
mutually exclusive exons, with 19a predominant in tumor
samples and 19b predominant in normal samples (Fig.
6). Exon 19 of VCL is a cassette exon that tends to be
skipped in these tumor samples.
ATP2B4 belongs to the family of ion transporters that
exhibits many isoforms with alternatively spliced exons
regulated in a tissue-specific manner. Exon 21 is a known
cassette-type exon that is found here in normal colon tis-
sue but is relatively reduced in tumor samples. ATP2B4
plays a role in cellular calcium homeostasis that may be
altered in tumor cells in parallel to the loss of ion trans-
porters seen at the gene level.
Workflow for parallel gene-level and exon-level analyses Figure 4
Workflow for parallel gene-level and exon-level analyses. The workflow illustrates two parallel lines of analysis corre-
sponding to gene-level (left) and exon-level (right) signal processing. The analyses converge at the level of MIDAS or the Splic-
ing Index, which implement statistical testing for alternative splicing. Signal estimation and MIDAS occur within the ExACT 
software and the filtering is accomplished mainly with simple Perl scripts. Yellow boxes represent files or data sets and green 
boxes represent processes or programs. Solid lines represent the main data flow and dotted lines are auxiliary flows, mainly for 
filtering.
CELs
iterPLIER DABG
Gene signal Exon signal
Exon
p-values 
MIDAS
AS p-values 
Gene list  AS exon
list
Gene 
Expression
Analysis
Gene-level
Analysis
Exon-level
Analysis
PCA, 
ANOVA
Filter outliers
SI Fold
change
Visuali-
zation
Filter gene
expression 
Validation and 
Interpretation
Meta-
probeset
Filter outliers
Exon signal
Exon signal
Filter exon
expression 
Gene signal
Gene signal
Meta-
probeset
PLIERBMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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An example of probeset-level intensities from two mutually exclusive exons (19a and 19b) of ACTN1 in a genomic context Figure 5
An example of probeset-level intensities from two mutually exclusive exons (19a and 19b) of ACTN1 in a genomic context. The 
probeset signals are normalized for each sample to the median signal for that sample across all the probesets in the view. This 
candidate splicing event was confirmed by RT-PCR. (BLIS viewer from Biotique.)BMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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PCR validation of candidate splicing events Figure 6
PCR validation of candidate splicing events. PCR products are derived from forward/reverse primers in well-annotated 
flanking regions as indicated under the gene name. The interpretation of each change in mobility is given to the right ("Incl", 
include; "Ext", extended). The sample numbers match those in the sample data information (see Methods). Note that in several 
cases, an unlabeled doublet band results from a heteroduplex forming between the PCR products. Controls are "Universal 
Total RNA" (Clontech), an independent colon RNA sample (BioChain) and a No Template Control ("NTC"). "M" is a DNA 
ladder marker.BMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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Variants of caldesmon (CALD1), a structural element link-
ing myosin and actin filaments, tend to include exon 6
and an extended exon 5 in normal cells. SLC3A2 encodes
the heavy chain of a heterodimeric solute carrier, but also
participates in integrin signaling [23,24]. Transcripts for
SLC3A2 are shifted to a higher molecular weight, indicat-
ing the inclusion of various combinations of exons 2, 3
and 4 in tumor samples that are much less prevalent in
normal tissue. Transcripts for the matrix protein Collagen
IV-3A (COL6A3) tend to include the cassette exons 3, 4
(not shown) and 6 (Fig. 6) in tumor samples to a greater
extent than in normal samples.
Cortactin (CTTN) also has roles both in cell adhesion and
organization of the cytoskeleton. Exon 11 is a cassette
exon that appears to be equally likely to be included or
skipped in normal tissue, but in the tumor samples, the
predominant form is inclusion of Exon 11. Fibronectin
(FN1) can be found in the extracellular matrix or at the
cell surface, and has a role in cell adhesion and migration.
A cassette exon, Exon 25, is more prevalent in normal tis-
sues than in tumor samples.
Tropomyosin 1 (TPM1) is also an actin-binding protein,
has a number of known splice variants, and is involved in
the contraction of muscle and in the cytoskeleton of non-
muscle cells. Since Exons 7 and 8 of TPM1 are mutually
exclusive exons of approximately the same size, the alter-
native amplificates were distinguished by a restriction
enzyme that cuts Ex7, but not Ex8. The fragments of Ex7
appear as two faster moving bands that are more prevalent
in the tumor samples.
Densitometric scans of the gel bands were used to quanti-
tate the observed splice variants (Additional file 5). The
ratio of the intensity of the alternative bands was calcu-
lated and compared across the tissue types as a log ratio.
The densitometric analysis suggests that the strongest and
most consistent changes occurred in ACTN1,  ATP2B4,
VCL and CALD1. TPM1 and CTTN also showed strong
splicing differences between the tissues, but with higher
variability. All of the tested events show a p-value of <
0.05 in the t-test across the tissues except for Ex6 of
COL6A3, for which the splice variants are more apparent
visually than in the scan.
Validation of previously reported splicing events
We also tested for the presence of several alternative splic-
ing events that were previously reported in colon cancers
[25-29], but were not strongly indicated by our statistical
analysis. The expected splicing events in Rac1,  VEGF,
SIAHBP1(PUF60) and MST1R  were weak or absent in
these samples (Fig. 7). Integrin beta4 (ITGB4) tends to
skip exon 35 and CD44 [4,5] shows alternative splicing in
about half the patient samples.
The relevant exons in CD44  did not score well in our
detection analysis, probably because of the inconsistency
in the splicing pattern. Densitometric analysis of CD44
(Additional file 5) confirms strong splice variation
Table 1: Differentially spliced genes in colon cancer detected by the exon microarray and confirmed by PCR.
Gene F1 R1 Known AS Event2 Confidence3 Preferential Inclusion of Splice Variants4 FC5
ACTN1 Ex18 Ex20 19a/19b are MEEs Good Ex19a in Tumor, 19b in Normal -1.05
ATP2B4 Ex20 Ex22 Ex21 is CE Good Ex21 in Normal +1.53
VCL Ex18 Ex20 Ex19 is CE Good Ex19 in Normal +1.22
CALD1 Ex5 Ex7 extended Ex5; Ex6 is CE Good extended Ex5 + Ex6 in Normal; Ex6 in Normal +1.36
SLC3A2 Ex1 Ex5 Ex2, 3, 4 are CEs Good Normal skips all exons -1.90
COL6A3 Ex2 Ex5 Ex3 and Ex4 are CEs Good Ex3 or Ex4 in Tumor -1.56
COL6A3 Ex5 Ex7 Ex6 is CE Good Ex6 in Tumor -1.56
CTTN Ex10 Ex14 Ex11 is CE Good Ex11 in Tumor -1.21
FN1 Ex24 Ex26 Ex25 is CE Good Ex 25 in Normal -1.86
TPM1 Ex6 Ex6 Ex7 Ex8 Ex7/Ex8 are usually MEEs Good Ex7 in Tumor; Ex8 in Normal +1.92
GK Ex19 Ex21 Ex20 is CE Mod. Ex20 in Tumor -1.01
MAST2 Ex7 Ex5 Ex9 Ex9 Ex7 alt. start? Mod. Ex7 Alt. Start in Normal +1.26
LGR5 Ex10 Ex11b Ex12 Ex12 extended Ex11; Ex11b is CE Weak extended Ex11 + Ex11b in Tumor -12.1
ZAK Ex11 Ex11b Ex11 Alt. 3' end Weak Alt. 3' end (Ex11b) in Normal -1.07
ZAK Ex16 Ex18 Ex17 appears constitutive Weak different 3' end of gene -1.07
FXYD6 Ex1 Ex4 Ex2 and Ex3 are rare CEs Very Weak Ex2 + Ex3 in Tumor +2.50
1 Exon locations of the F (forward) and R (reverse) PCR primers. 2 Known Alternative Splicing Event As determined from RefSeq, full length mRNAs 
and ESTs on the UCSC Genome Browser. 3 Relative confidence in the interpretation. 4 Interpretation of the PCR results in terms of transcript 
structure. 5 Fold change at the gene level. (-) means that the signal is lower in Tumor. Abbreviations: Ex, exon; CE, cassette exon; MEE, mutually 
exclusive exon; Alt., alternative.BMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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between the tissues, but with a high variability across sam-
ples. Note that the advanced tumor sample in Lane 13, the
most predictive for our differential splice patterns, does
not display alternative splicing of CD44.
VEGF  has a potentially complex splicing pattern, with
possible combinations of Ex6a, Ex6b, extended Ex6a and
Ex7. McCullough et al. [30] attempted to resolve this com-
plexity with a mass spectrometry-based method that indi-
cated that the majority of the transcripts in normal colon
lack Exon 6, whereas we find that about half of the tran-
scripts migrate consistently with inclusion of Exon 6. The
results from CD44 and VEGF underscore the difficulty of
detecting relatively subtle alterations in small, heteroge-
neous sample populations.
Pathway analysis of validated splicing events
Analysis of the alternatively spliced genes with MetaCore
software produced a network (Fig. 8) that can be roughly
divided into two areas of cellular function. Cell motility
and organization of the actin cytoskeleton functions
include the alternatively spliced products of TPM1,
ACTN1, VCL, CALD1 and CTTN, while cell adhesion and
matrix organization includes those of COL6A3, FN1, VCL,
ITGB4 and CD44.
Comparison to bioinformatic methods of estimating 
alternative splicing
Several bioinformatic approaches have been developed to
identify splice variation between normal tissue types or
normal versus tumor tissues. These methods rely on map-
ping ESTs or mRNAs onto RefSeq transcripts or genomic
sequence, making frequency counts of various isoforms,
and applying a statistical test to detect differential inclu-
sion of exons in different tissues. The methods vary some-
what in research focus, basic algorithms, statistical
methods (e.g., Z-statistics vs. Fischer's exact test), EST
source libraries, and mechanisms of normalizing or filter-
ing out differential gene expression, but the essential
approach is similar. We compared our empirical data
from the exon array to three lists of the cancer-associated
splicing events computationally predicted in Wang, et al.
[31], the virtual SAGE-filtered list of Kirschbaum-Slager et
al. [32] and in the BASD database described in Hui, et al.
[33]. When evaluating the results, it must be kept in mind
that these bioinformatic approaches assay either tumors
generally or a range of tumor types, but not specifically
colon cancer (as in our study).
The splicing events derived from the three methods were
mapped to Unigene gene symbols where possible and
compared to the top 200 candidate splicing events from
the exon array, which corresponds to 169 genes (see Addi-
tional file 3). Our list of candidates matched approxi-
mately an equal proportion of each EST-derived list,
between 1.92% and 1.97% of the total genes in each set:
12/625 for Kirschbaum-Slager et al., 33/1733 for BASD
and 13/660 for Wang et al. Altogether, 53 of our 169 can-
didate genes are found in at least one list. A simple chi-
squared test indicates that elements of each list are highly
PCR validation of previously reported colon cancer-specific splicing events Figure 7
PCR validation of previously reported colon cancer-specific splicing events. See Fig. 6 for description.BMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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overrepresented in each of the other lists (with p-values <
0.01). The strongest association between the exon-array
candidates was with the BASD list, most likely because of
the increased statistical power of this larger data set. The
EST-based prediction sets showed a similar distribution of
association to each other as our candidate gene list did to
each of them.
Among our 14 validated candidates, three (CALD1, FN1,
TPM1) appeared in the BASD list, two (CALD1,  GK)
appeared on the list of Wang et al., and none appeared on
the list of Kirschbaum-Slager et al. Of the six previously
reported alternatively spliced genes tested here, two
(CD44 and VEGF) are found in BASD, two (MST1R and
VEGF) are found in the list of Wang et al. and one (RAC1)
appears on the list of Kirschbaum-Slager et al. CD44,
SIAHBP1 and VEGF do appear in our list of 169 candidate
genes, but none ranked in the top 100.
Discussion and Conclusion
There are many design differences between the exon array
and the U133 Plus 2: feature size, the number of probes
per probeset, the number of probesets per transcript,
background calculation, the assay procedure, etc. The
most obvious difference is that the exon array interrogates
exons/subexons throughout the transcript, while the
U133 Plus 2 generally targets only the 3' end. Alternative
splicing and, particularly, alternative polyadenylation
sites may account for substantial differences in gene signal
estimation. Furthermore, our method of averaging the sig-
nal value of multiple probesets targeting the same tran-
script on the U133 Plus 2 is only a rough compromise.
Despite the many differences, the gene-level comparison
demonstrated a reasonable correlation in signals for genes
that are significantly different between tissue types. The
most notable difference in signal estimations is the shift of
apparently low expressing genes on the U133 Plus 2 array
to higher signals on the exon array. Since the exon array
generally contains 3 to 4 times as many probes per tran-
script as the U133 Plus 2 array and the probesets are dis-
tributed throughout the transcript cluster, the exon array
may be more sensitive in detecting a subset of low express-
ing genes, at least in this data set. Resolution of, for exam-
ple, the portability of results between the arrays types, or
Network containing products of alternatively spliced genes in colon cancer Figure 8
Network containing products of alternatively spliced genes in colon cancer. Proteins affected by alternative splicing 
are indicated with a red disk. Proteins concerned with cell or matrix adhesion are generally to the left while those concerned 
with cell motility and the actin cytoskeleton occupy the center and right. "PMCA4" is an alias for ATP2B4.BMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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the characteristics of transcripts that are differentially
detected, will require several dedicated studies, for which
data is becoming available.
Among the 160 genes differentially expressed in the Core
gene set, 60 have been previously identified as participat-
ing in cancers, with 21 specifically in colon or colorectal
cancer. Almost one third of the up-regulated genes are part
of a tightly interconnected network involved in mitosis,
cell cycle control, cell proliferation, invasion, matrix
remodeling and Wnt signaling. Constitutive activation
within the Wnt signaling pathway has been a prevalent
theme in colon cancers, in particular the role of β-catenin
[18,34]. Eight of the over-expressed genes here (BIRC5,
MMP7, VEGF, ENC1, CCND1, STRA6, MET and CLDN1)
are targets of Wnt/β-catenin regulation and two other
Wnt-associated genes, SOX9 and HIG2, are up-regulated
in these colon cancer samples.
Twenty nine of the tumor-expressed genes have unknown
or weakly annotated functions, but several may be
involved in cell proliferation or apoptosis (MCTS1, SIL,
HSPA5BP1, WDR18 and IFITM1) and at least eight have
previously been associated with various cancers (Addi-
tional file 1). Thirteen putative transcriptional regulators
and most of the genes classified as signal transducers have
unknown biological roles. Another seven genes annotated
only as "hypothetical protein" or "open reading frame"
(MGC4677,  C12orf11,  FLJ10726,  C6orf167,  FLJ31153,
FLJ20272, DKFZp762E1312, KIAA1217 and FLJ10719) are
strongly expressed above background. The expanded anal-
ysis based primarily on ab-initio exon predictions identi-
fied 38 more genes with significant expression even
though they completely lack previous annotation (Addi-
tional file 2). These transcripts with unknown functions
may represent a novel set of targets for study in colon can-
cer oncology and demonstrate the exploratory power of
an inclusive array design.
We have identified a number of genes that are differen-
tially spliced between normal and cancerous tissue. Most
of the tissue-specific alternative splicing events that were
experimentally validated occurred in genes involved in
cytoskeletal structure, the extracellular matrix or cell-cell
interactions. Some of these events are reported splice var-
iants that occur in a tissue-specific manner and may repre-
sent a loss of tissue function as colonic epithelial and
smooth muscle cells dedifferentiate, rather than abetting
transformation or metastasis. Determination of the role of
these splice events requires more detailed study, but in
most cases these genes have previously been implicated
with active roles in the progression of tumors.
Five of the genes (TPM1, ACTN1, VCL, CTTN and CALD1)
that we found to be alternatively spliced in colon cancer
have actin-binding domains and play a direct role in the
organization or structure of the cytoskeleton. Remodeling
of the cytoskeleton is fundamental in proliferation, apop-
tosis, cell invasion and metastasis [35].
TPM1 appears to act as a tumor suppressor by promoting
anoikis (apoptosis induced by cell detachment) [36].
Down-regulation of TPM1 by oncogenic transformation
results in a loss of actin stress fibers [37,38], whereas res-
toration of TPM1 inhibits cell migration in metastatic cell
lines [39]. A splice variant of one of the low molecular
weight isoforms of tropomyosin has been found specifi-
cally in association with colonic polyps and adenomas,
but not normal colon tissue [40].
Actinin is a component of stress fibers and links the
cytoskeleton to adherens-type junctions. It plays a role in
cell migration probably by facilitating detachment of
focal adhesions distal to the direction of movement [41].
Alternative splicing of actinin-4, which has a high
sequence similarity to ACTN1, apparently leads to an
abnormal cytoskeleton in small cell lung cancer [42].
ACTN1 also has a binding site for VCL, and the two pro-
teins cooperate to organize the cytoskeleton at adhesion
junctions [43].
CALD1 binds actin and responds to calmodulin to pro-
mote stress fibers and focal adhesions, and CALD1-defec-
tive cells are highly impaired in motility [44]. In cells
transformed by Kaposi sarcoma-associated herpes virus
(KSHV) or v-erbB, hypermethylation of CALD1  and
recruitment of its product into membrane complexes is
linked to the loss of cytoskeletal microfilaments [45,46].
CTTN, frequently overexpressed in breast cancer and
squamous cell carcinomas, is highly enriched at tumor
invasion fronts [47,48]. Two conformational forms of
CTTN are known, with both forms present in normal cells,
but the apparently larger one (p85) is more prevalent in
colorectal cancers [47]. Two splice variants that affect cell
mobility have been previously identified: SV-1 (lacking
Exon 11) and SV-2 (lacking Exons 10 and 11). SV-1 and
full-length CTTN were equally abundant in normal cells
while SV-2 was barely detectable. SV-1, but not SV-2, can
bind and crosslink actin, but overexpression of either
form interferes with cell migration [49]. Our results indi-
cate that transcripts with or without Exon 11 are approxi-
mately equal (in agreement with previous data), but
transcripts carrying Exon 11 (i.e., full length) are relatively
more abundant in colon cancer samples, suggesting that
these cells may be more competent for motility.
Alternative splicing of FN1, CD44 and COL6A3 may play
some role in matrix remodeling and/or cell migration in
colon cancer, though COL6A3 has not been previouslyBMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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implicated in this role. Fibronectin was one of the consist-
ently up-regulated genes in an artificial selection for
highly metastatic cell lines, which also identified ACTN1
and several collagens [50]. Two splice variants of FN1
have been implicated in the neo-vasculature of a variety of
human tumors but not in normal adult tissues, however
the role of these species in tumor-related angiogenesis is
unclear [51]. Alternatively spliced FN1 containing an extra
domain has been found frequently in cancers [3], whereas
we find preferential skipping of Exon 25 in tumor tissues.
CD44 is involved in both cell-matrix and cell-cell interac-
tions as well as connections to the actin cytoskeleton via
ankyrin. The variably spliced region of CD44 (exons 6–
15) is preferentially included in many cancer types and
appears to affect cell migration, invasion and metastasis
[5].
Integrin ITGB4 interacts with the intermediate filament
network, stimulates the Ras and PI3-K signaling pathways,
and appears to be important for cell invasion in colon
cancer [52,53]. SLC3A2, which functions in transmem-
brane transport, associates with integrins and appears to
participate in integrin-mediated anchorage-independent
cell growth and tumorigenesis in 3T3 fibroblasts [23,54].
The inclusion of several exons of SLC3A2 in colon cancer
transcripts may represent a tumor-specific alteration of its
role in integrin signaling.
Of the eleven differentially spliced genes we found or con-
firmed, ten are involved in the organization of the
cytoskeleton or interaction with the matrix or other cells.
Seven of these genes (TPM1, CALD1, CTTN, FN1, CD44,
ITGB4 and SLC3A2) have previously been implicated in
cancers, and, in five cases, specific splice variants are cor-
related with the cancerous state. This grouping may repre-
sent a coherent, and possibly coordinated, set of
alterations which may impact cell mobility and extracellu-
lar interactions. A similar concentration of splice variants
was found in mouse brain, where targets of the Nova
splicing regulon are clustered into functions affecting syn-
aptic transmission and cell morphology. In fact, the tar-
gets appear to act as a modular network that impacts not
only signaling functions, but also specifically the actin
cytoskeleton, extracellular matrix and cell-cell adhesion
[55]. It is possible that a similar splicing network is altered
in colon cancer to produce the complex of interacting
splice variants seen in this study. Such patterns may be
more apparent in a highly parallel genome-wide exon
analysis than in traditional methods involving gene-by-
gene searches.
One assumption of this type of analysis is that biologi-
cally important splicing changes would consistently
appear in samples of a particular category (i.e., colon can-
cer). In some cases, our samples did not reproduce some
previously reported events (Rac1, VEGF, SIAHBP1, and
MST1R), or else the changes were sporadic (CD44). Fur-
thermore, we find differences even in normal samples
with regard to Exon 6 of VEGF compared to the mass spec-
trometry results of McCullough et al. [30]. In fact, the
most relevant splicing change in VEGF for tumorigenesis
may be a splice variant involving Exon 8 [56]. In this situ-
ation, it may be difficult to resolve what the normal and
abnormal states are for VEGF. Inconsistent results may be
due to differences in samples, experimental procedures,
analyses or interpretations, suggesting that conclusions
about subtle changes in splicing may need to be rein-
forced by multiple sources. On the other hand, many of
our validated splicing events have been observed in sev-
eral other instances. Nearly identical patterns of differen-
tial alternative splicing was found in colon tumors by
Okumura et al. for TPM1, ACTN1 and ITGB4, and these
patterns were even more emphatic in tumor cell lines.
Interestingly, differential splicing of CD44 in colon cancer
was not observed in that study [57]. ITGB4 and TPM1
were identified by an EST-based analysis, and experimen-
tally validated as differentially spliced in several tumor
types [58]. The alternative splicing of CTTN is consistent
with protein alterations seen in association with colon
cancer [47]. Our sample set ranged from well differenti-
ated to poorly differentiated (i.e., advanced) tumors, yet
ACTN1, ATP2B4, VCL and CALD1 show strong and con-
sistent changes across our samples (Additional file 5). The
presence of these splice variants in multiple tumor stages
argues that they must be both early and persistent events.
Finally, differences in splicing patterns may be due to bio-
logically important differences in cancer etiology, and
therefore be useful indicators of tumor subtypes or stages.
With the large amount of EST and genomic data available,
a great deal of useful information may be gained from in
silico  prediction of transcript isoforms. Validation rates
from such methods have been fairly high and the resulting
pattern of predictions are mostly in line with empirical
data. There are a number of potential hazards in this
approach: EST libraries are highly variable in quality and
reliability, it is difficult to account for differential gene
expression, and tissues and individual genes are unevenly
represented. Almost 45% of EST libraries are from cancer
samples [33] and 70% of mRNAs in GenBank are cloned
from tumor samples [59], leading to a strong bias against
identifying isoforms present in normal tissues. Also, in
spite of various methods to remove or normalize differen-
tially expressed genes, this factor may lead to overpredic-
tion [32]. The exon array addresses many of the
difficulties by providing an empirical platform that is
unbiased with regard to tissue or gene representation, and
allows for direct normalization of differential gene expres-
sion. While a substantial proportion (32%) of our top
candidates for alternative splicing matched predictionsBMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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from three EST-derived methods, only four of our vali-
dated splicing events appeared among the 2797 genes
with bioinformatically predicted splice variants. This sug-
gests that there are substantial gaps in current EST data-
bases that must be addressed empirically.
The splicing changes seen here are not necessarily as dra-
matic as seen in a previous study of 16 pure normal tissues
with an exon-based microarray (Clark et al., in prep.). This
highlights the subtlety of most splicing events, which are
typically not an all-or-none phenomenon, so sample size
and homogeneity are important considerations. In spite
of limitations which are frequently encountered in cancer
and other tissue studies in humans, such as a modest sam-
ple size, heterogeneous tissues, and multiple categorical
variables (tumor stage, gender, and individual patient var-
iation), we were able to identify and validate a number of
candidate colon cancer-specific splicing events. Explora-
tion of alternative splicing will promote understanding of
cancer etiology and may provide therapeutic targets and
diagnostic markers [2,3].
Methods
Sample preparation and array hybridization
Ten matched-pairs (20 total RNA samples) of human
colon primary tumor and adjacent normal tissue Total
RNA (P/N R8235090-PP-10) were purchased from Bio-
chain Institute, Inc. (Hayward, CA). Tumors were charac-
terized as poorly (2 samples), moderately (4) or well (4)
differentiated. Adjacent normal tissue may include both
colonic epithelial and smooth muscle tissue. Patient
information and associated .CEL files are available from
Affymetrix, Inc. [60].
One µg of each sample was processed using a pre-com-
mercial version of the Affymetrix GeneChip Whole Tran-
script Sense Target Labeling Assay [61]. Pre-commercial
versions of the GeneChip WT cDNA Synthesis Kit, WT
cDNA Amplification Kit, and WT Terminal Labeling Kit
(Affymetrix, Inc., Santa Clara, CA), containing identical
formulations to the commercial kits, were used for target
preparation. Eight µg of cRNA were input into the second-
cycle cDNA reaction. Hybridization cocktails containing 3
to 4 µg of fragmented, end-labeled cDNA were prepared
and applied to GeneChip Human Exon 1.0 ST arrays.
Hybridization was performed for 16 hours using the
MES_EukGE-WS2v5_450-DEV fluidics wash and stain
script (pre-commercial FS450_0001 script). Arrays were
scanned using the Affymetrix GCS 3000 7G and Gene-
Chip Operating Software v. 1.3 to produce .CEL intensity
files.
Data analysis algorithms
Signal estimates were derived from the CEL files of the 20
samples by quantile sketch normalization using the PLIER
algorithm for probeset (exon-level) intensities and Iter-
PLIER for gene-level intensities [11]. Presence/absence of
exons was determined by "Detection Above Background"
(DABG), using surrogate GC mismatch intensities.
Candidate exons for alternative splicing were detected
using a Splicing Index and the MIDAS algorithm [11]. The
Splicing Index (SI) represents the log ratio of the exon
intensities between the two tissues after normalization to
the gene intensities in each sample: SIi = log2((e1i/g1j)/
(e2i/g2j)), for the i-th exon of the j-th gene in tissue type 1
or 2. The splicing indices are then subjected to a t-test to
probe for differential inclusion of the exon into the gene.
MIDAS employs the Splicing Index in an ANOVA model
to test the hypothesis that no alternative splicing occurs
for a particular exon. The ExACT program implements the
MIDAS algorithm and is available for download. Default
parameters were used in all algorithms.
Data analysis
ANOVA p-values and fold changes for gene expression
were calculated using Partek Genomic Suite 6.2 (Partek
Inc., St. Louis, MO) and biochemical/regulatory network
mapping of significant genes was performed using Meta-
Core 3.2.1 software (GeneGo Inc., St. Joseph, MI). Patient
3 was removed as an outlier due to aberrant behavior in
PCA, which improved the signal-to-noise ratio for dis-
crimination by tissue type. Noise ratios also showed that
gender, patient and tumor differentiation categories were
relevant as factors in the analysis.
For efficient functioning of the alternative splicing algo-
rithms, exons and genes with low expression were
removed from the analysis by the following criteria (see
Fig. 4). Exons were accepted if they had a DABG p-value <
0.05 in at least 50% of the samples in either tissue. Genes
were accepted if either: a) at least 50% of the core exons in
at least 50% of samples in both tissues had a DABG p-
value < 0.05 or b) if the IterPLIER gene-level signal inten-
sity exceeded a particular threshold, depending on the fil-
tering version. The gene-level requirement is necessary
because alternative splicing is meaningless if the gene is
not significantly expressed in both tissues.
Subsequent to filtering, the gene-level and exon-level
PLIER intensities were jointly processed by either MIDAS
or SI. Exons from the Full meta-probeset that associate
with these Core genes were included in the analysis. The
results were filtered for a Slicing Index > 0.5, and high
scoring hits were taken for further analysis. Candidate
exons were visually inspected in genomic context (Inte-
grated Genome Browser, Affymetrix Inc. or BLIS 6.2.1,
Biotique Systems Inc., Reno, NV) to ensure that exon-level
expression patterns were consistent with potential alterna-
tive splicing. For example, exon intensities that stronglyBMC Genomics 2006, 7:325 http://www.biomedcentral.com/1471-2164/7/325
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and uniformly deviate from that of adjacent well-anno-
tated exons in the same gene may indicate cross hybridi-
zation, poorly performing probes or absent target.
Visualization at the probeset level is also useful to insure
that the signals are consistent within tissue groups, that
neighboring constitutive exons are comparably expressed
and that multiple probesets interrogating the same exon
have similar signals.
Finally, possible splicing patterns were determined by
mapping the probesets to publicly available mRNA and
EST sequences on the UCSC Genome Browser [62] via
BLAT. Candidates consistent with known examples of
alternative splicing are more likely to prove to be true pos-
itives, but this approach will also suppress the discovery of
novel splicing events. In addition, the BLAT results indi-
cate whether there similar sequences elsewhere in the
genome that may lead to false signals by crosshybridiza-
tion.
Array Comparison
For comparison of gene-level expression between the
Exon Array and the Human Genome U133 Plus 2.0 Array,
total RNA from 11 different tissues were purchased from
Ambion, Inc. (Austin, Texas). In brief, three assay repli-
cates were prepared from each tissue with 5 µg (3' IVT) or
1 µg (WTA) of RNA according to the Expression Analysis
Technical Manual or the Whole Transcript Sense Target
Labeling Assay Manual, and hybridized to the Exon and
the U133 Plus 2 arrays. Signal estimations were generated
with PLIER, using the Core meta-probeset in the case of
the Exon Array. The signals were quantile normalized
within tissues and then median normalized across the tis-
sue types. The signal was transformed and variance stabi-
lized by log2(signal +16). The CEL files and signal
estimation data are available from Affymetrix [60]. A 1-
way ANOVA was performed with the Partek Genomics
Suite across all tissue types. P-value cutoffs were deter-
mined by Bonferroni multiple test correction with thresh-
olds at 0.05, 0.001 and 10-8. Genes which were
significantly different in any pair of tissue types were kept
for further analysis. Transcript clusters (Exon) and
probesets (U133 Plus 2) were mapped to each other
according to the file "HuEx-1_0-st-v2 Transcript Cluster
ID Mappings to HG-U133 Plus 2.0" [63]. Multiple U133
Plus 2 probesets which target the same transcript cluster
were averaged to obtain the signal estimate. The subse-
quent comparisons were generated with the Partek
Genomics Suite.
RT-PCR validation
Approximately 2 µg of total RNA was reverse transcribed
to cDNA using the TaqMan Reverse Transcription Rea-
gents Kit per manufacturer's instructions (Applied Bio-
sciences) with a combination of oligo dT and random
hexamers as primers. PCR was carried out for 35 cycles
using Taq Polymerase (Promega) per manufacturer's
instructions with approximately 50–100 ng of cDNA as
template. PCR products were separated on 2.5% agarose
gels and stained with ethidium bromide for visualization.
All RT-PCR primer sequences are included in Additional
file 4.
In order to discriminate between the two mutually exclu-
sive exons (Ex7 & Ex8) of the same size in the TPM1 gene,
the resulting PCR products were distinguished with an
enzyme that cuts only one of the exons. 30 µl of PCR
product was digested with 1 U of PvuII (New England
Biolabs) at 37°C for 1 hour per manufacturer's instruc-
tions. PvuII cuts a sequence (CAGCTG) present in Ex7,
but not in Ex8. Thus, RT-PCR products generated from
mRNAs containing Ex7 are cut into two smaller, faster
migrating segments when separated on a 2.5% agarose
gel.
Densitometric analysis of the RT-PCR gels was carried out
using AlphaEaseFC 4.0 (Alpha Innotech Corp., San Lean-
dro, CA) software per manufacturer's recommendations.
A ratio of two isoforms was generated using the sum of all
pixel intensities within an identically sized region con-
taining each band. In some cases, where appropriate,
intensities from multiple bands were added together to
generate a single value representing an isoform. In order
to determine if the change in isoform expression was sta-
tistically significant, a simple two-tailed t-test was carried
out on the isoform ratios by grouping the 10 samples
from either "tumor" or "normal" tissue. A summary of the
results is included in Additional file 5.
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Additional file 1
Table_A1_differential_CORE_genes. Genes in the Core metaprobe set 
which are differentially regulated in colon cancer. The log fold change is 
shown for Normal relative to Tumor samples, which is negative for up-reg-
ulated genes. "Cancer" Indicates that the gene has been implicated in var-
ious cancers. Question marks indicate an unproven association. "CRC" 
indicates that the gene has been implicated specifically in colon or color-
ectal cancer. Gene annotations are according to the Affymetrix file HuEx-
1_0-st-transcript-annot.csv (NCBI build 35, UCSC hg17). Abbrevia-
tions: Exc., extracellular; proc., processing; R & R, recombination and 
repair.
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